QuickAST-DX SA
0.1 FTEThe score of QuickAST-DX shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -83 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
QuickAST-DX's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 30 Sep 2025
- Year ended 31 Dec 2023filed on 31 Jul 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
QuickAST-DX's financial analysis
- Solvency-1467.7%sector median: 34.8%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of QuickAST-DX
QuickAST-DX's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0778.858.926
- VAT number
- BE0778858926
- Peppol
- Registered · 0208:0778858926 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 20 Dec 2021
- Registered office
- 9051 Ghent
- Size
- Micro · 0.1 FTE
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Manufacture of other inorganic basic chemicals (NACE 20130)
QuickAST-DX (SA) has been based in Ghent since 2021, active in: manufacture of other inorganic basic chemicals. For 2025, it reports a net loss of 55,278 € and equity of −356,484 €; its revenue is not published. With 0.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -1467.7%, below the median of its sector (34.8%).
Companies similar to QuickAST-DX
Companies in the same business, of comparable size and area, outside its group.
- Celltest Research and experimental development on natural sciences and engineering Woluwe-Saint-Lambert · balance sheet 18,489 €
- RheADC Manufacture of basic pharmaceutical products Leuven · balance sheet 31,395 €
- 4K Services Belgium Research and experimental development on natural sciences and engineering Etterbeek · balance sheet 59,971 €
- OncoRNA Research and experimental development on natural sciences and engineering Charleroi · balance sheet 20,034 €
- P & X Medical Research and experimental development on natural sciences and engineering Wevelgem · balance sheet 50,706 €
- Inchinn Therapeutics Manufacture of basic pharmaceutical products Charleroi · balance sheet 51,394 €
- Mentana DX Research and experimental development on natural sciences and engineering Evergem · balance sheet 229,998 €
- Biocubik Research and experimental development on natural sciences and engineering Seraing · balance sheet 592,794 €
Frequently asked questions about QuickAST-DX
What is the revenue of QuickAST-DX?
QuickAST-DX files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of QuickAST-DX?
In Belgium, the VAT number is the company number prefixed with BE: BE0778858926 for QuickAST-DX, if the company is VAT-registered. Its company number (CBE) is 0778.858.926.
Where is the registered office of QuickAST-DX?
According to the CBE register, the registered office of QuickAST-DX is in 9051 Ghent.
What is the equity of QuickAST-DX?
At the close of the 2025 financial year, the equity of QuickAST-DX amounts to -356,484 €, a solvency of -1467.7% of total assets.
How many people work at QuickAST-DX?
0.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages QuickAST-DX?
The register lists 2 active mandates at QuickAST-DX. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of QuickAST-DX
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →